TD Cowen Keeps Hold Rating on Standard BioTools, Reduces Price Target to $1.35
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Should l Buy LAB?
Source: Benzinga
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, fostering a collaborative environment for sharing market intelligence.
Market Success: The platform is designed to help traders win in the markets every day by providing accurate and timely stock market information.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LAB
Wall Street analysts forecast LAB stock price to rise
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 1.110
Low
1.35
Averages
1.35
High
1.35
Current: 1.110
Low
1.35
Averages
1.35
High
1.35
About LAB
Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Standard BioTools to Release Q4 and Full Year 2025 Financial Results
- Earnings Announcement: Standard BioTools Inc. will publish its fourth quarter and full year 2025 financial results on February 24, 2026, after U.S. market close, which is expected to provide investors with the latest insights into the company's operational performance.
- Technological Edge: As a leading solutions provider in biomedical research, Standard BioTools leverages its proprietary mass cytometry and microfluidics technologies to help researchers develop better medicines faster, thereby transforming scientific discoveries into improved patient outcomes.
- Market Focus: The company addresses pressing needs in translational and clinical research, particularly in oncology, immunology, and immunotherapy, highlighting its significant role in the biotechnology sector.
- Global Collaboration Network: Standard BioTools collaborates with leading academic, government, pharmaceutical, and biotechnology laboratories worldwide, aiming to provide reliable and repeatable insights into health and disease, further solidifying its market leadership.
See More
Standard BioTools Completes Sale of SomaLogic to Illumina
- Significant Transaction Value: Standard BioTools completed the sale of SomaLogic to Illumina for $350 million in cash, with an additional potential earnout of up to $75 million, bringing the total transaction value to $425 million, marking a major milestone in the company's strategic transformation.
- Strong Cash Reserves: Following the transaction, Standard BioTools estimates a cash and cash equivalents balance of approximately $550 million, providing robust financial resources for future M&A activities, thereby accelerating growth in a competitive industry landscape.
- Profitability Outlook: The company is on track to achieve positive adjusted EBITDA by 2026, reflecting improved operational efficiency and indicating a strong recovery capability in market competition, which enhances investor confidence.
- Long-Term Revenue Potential: Standard BioTools will receive a 2% royalty on net revenues from SOMAmer-based products for the next ten years, creating a stable revenue stream that supports ongoing innovation and market expansion strategies.
See More
STANDARD BIOTOOLS FINALIZES SALE OF SOMALOGIC TO ILLUMINA
- Sale Announcement: Standard Biotools has completed the sale of Somalogic to Illumina.
- Strategic Move: This acquisition is expected to enhance Illumina's capabilities in the field of genomics and proteomics.
See More
Neogen Corp (NEOG) Reports Q2 Earnings Beat, Shares Surge 28%
- Earnings Beat: Neogen Corp reported adjusted earnings of $0.10 per share for Q2, surpassing market expectations of $0.06, which significantly boosts investor confidence in the company's profitability.
- Sales Growth: The company achieved quarterly sales of $224.691 million, exceeding the forecast of $207.846 million, indicating strong market demand and promising future growth potential.
- Stock Surge: Following the earnings report, Neogen's stock price surged 28% to $9.44 on Thursday, reflecting a positive market sentiment and potentially attracting more investor interest.
- Guidance Upgrade: Neogen raised its FY26 sales guidance above market estimates, demonstrating confidence in future performance, which may further drive stock price appreciation and enhance competitive positioning in the market.
See More
Standard BioTools Projects $185 Million Revenue for 2025
- Quarterly Revenue Expectations: Standard BioTools anticipates approximately $56 million in combined revenue for Q4 2025, with about $24 million from continuing operations, indicating stable growth potential in the life sciences tools sector.
- Full-Year Performance Outlook: The company projects a total revenue of around $185 million for 2025, with approximately $85 million from continuing operations, reflecting ongoing development in its core business and strong market demand.
- Enhanced Strategic Flexibility: CEO Michael Egholm noted that the sale of SomaLogic to Illumina is on track to close in the first half of 2026, which is expected to provide the company with about $550 million in cash, significantly enhancing its capacity for future strategic investments.
- Stock Performance: Standard BioTools shares closed at $1.28 on Wednesday, up 0.78%, indicating market recognition of the company's growth potential moving forward.
See More
Labrador Gold Acquires 16.67M Subscription Receipts from Northern Shield for $1M
- Financing Transaction: Labrador Gold has acquired 16,666,667 Subscription Receipts from Northern Shield at a price of $0.06 each, totaling an investment of $1,000,000.02, indicating the company's proactive approach in resource investment.
- Business Transformation: This transaction allows Labrador Gold to transition from a pure exploration company to an exploration and investment issuer, enabling it to maintain exploration activities while also making equity investments in other resource companies, thereby enhancing business diversification.
- Shareholder Approval Conditions: The release of the investment funds is contingent upon receiving approval from Labrador Gold's shareholders and regulatory bodies, and if not approved, the funds will be returned, reflecting the company's cautious approach to risk management.
- Future Rights: As long as Labrador Gold retains a 10% equity interest in Northern Shield, it will have pre-emptive rights to participate in future financings and the right to appoint a technical advisor, further solidifying its influence within Northern Shield.
See More
Standard BioTools to Release Q4 and Full Year 2025 Financial Results
- Earnings Announcement: Standard BioTools Inc. will publish its fourth quarter and full year 2025 financial results on February 24, 2026, after U.S. market close, which is expected to provide investors with the latest insights into the company's operational performance.
- Technological Edge: As a leading solutions provider in biomedical research, Standard BioTools leverages its proprietary mass cytometry and microfluidics technologies to help researchers develop better medicines faster, thereby transforming scientific discoveries into improved patient outcomes.
- Market Focus: The company addresses pressing needs in translational and clinical research, particularly in oncology, immunology, and immunotherapy, highlighting its significant role in the biotechnology sector.
- Global Collaboration Network: Standard BioTools collaborates with leading academic, government, pharmaceutical, and biotechnology laboratories worldwide, aiming to provide reliable and repeatable insights into health and disease, further solidifying its market leadership.
See More
Standard BioTools Completes Sale of SomaLogic to Illumina
- Significant Transaction Value: Standard BioTools completed the sale of SomaLogic to Illumina for $350 million in cash, with an additional potential earnout of up to $75 million, bringing the total transaction value to $425 million, marking a major milestone in the company's strategic transformation.
- Strong Cash Reserves: Following the transaction, Standard BioTools estimates a cash and cash equivalents balance of approximately $550 million, providing robust financial resources for future M&A activities, thereby accelerating growth in a competitive industry landscape.
- Profitability Outlook: The company is on track to achieve positive adjusted EBITDA by 2026, reflecting improved operational efficiency and indicating a strong recovery capability in market competition, which enhances investor confidence.
- Long-Term Revenue Potential: Standard BioTools will receive a 2% royalty on net revenues from SOMAmer-based products for the next ten years, creating a stable revenue stream that supports ongoing innovation and market expansion strategies.
See More
STANDARD BIOTOOLS FINALIZES SALE OF SOMALOGIC TO ILLUMINA
- Sale Announcement: Standard Biotools has completed the sale of Somalogic to Illumina.
- Strategic Move: This acquisition is expected to enhance Illumina's capabilities in the field of genomics and proteomics.
See More
Neogen Corp (NEOG) Reports Q2 Earnings Beat, Shares Surge 28%
- Earnings Beat: Neogen Corp reported adjusted earnings of $0.10 per share for Q2, surpassing market expectations of $0.06, which significantly boosts investor confidence in the company's profitability.
- Sales Growth: The company achieved quarterly sales of $224.691 million, exceeding the forecast of $207.846 million, indicating strong market demand and promising future growth potential.
- Stock Surge: Following the earnings report, Neogen's stock price surged 28% to $9.44 on Thursday, reflecting a positive market sentiment and potentially attracting more investor interest.
- Guidance Upgrade: Neogen raised its FY26 sales guidance above market estimates, demonstrating confidence in future performance, which may further drive stock price appreciation and enhance competitive positioning in the market.
See More
Standard BioTools Projects $185 Million Revenue for 2025
- Quarterly Revenue Expectations: Standard BioTools anticipates approximately $56 million in combined revenue for Q4 2025, with about $24 million from continuing operations, indicating stable growth potential in the life sciences tools sector.
- Full-Year Performance Outlook: The company projects a total revenue of around $185 million for 2025, with approximately $85 million from continuing operations, reflecting ongoing development in its core business and strong market demand.
- Enhanced Strategic Flexibility: CEO Michael Egholm noted that the sale of SomaLogic to Illumina is on track to close in the first half of 2026, which is expected to provide the company with about $550 million in cash, significantly enhancing its capacity for future strategic investments.
- Stock Performance: Standard BioTools shares closed at $1.28 on Wednesday, up 0.78%, indicating market recognition of the company's growth potential moving forward.
See More
Labrador Gold Acquires 16.67M Subscription Receipts from Northern Shield for $1M
- Financing Transaction: Labrador Gold has acquired 16,666,667 Subscription Receipts from Northern Shield at a price of $0.06 each, totaling an investment of $1,000,000.02, indicating the company's proactive approach in resource investment.
- Business Transformation: This transaction allows Labrador Gold to transition from a pure exploration company to an exploration and investment issuer, enabling it to maintain exploration activities while also making equity investments in other resource companies, thereby enhancing business diversification.
- Shareholder Approval Conditions: The release of the investment funds is contingent upon receiving approval from Labrador Gold's shareholders and regulatory bodies, and if not approved, the funds will be returned, reflecting the company's cautious approach to risk management.
- Future Rights: As long as Labrador Gold retains a 10% equity interest in Northern Shield, it will have pre-emptive rights to participate in future financings and the right to appoint a technical advisor, further solidifying its influence within Northern Shield.
See More
